Assetmark Inc. Has $978,000 Stock Position in Icon Plc $ICLR

Assetmark Inc. increased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 80.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,835 shares of the medical research company’s stock after buying an additional 3,938 shares during the quarter. Assetmark Inc.’s holdings in Icon were worth $978,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ICLR. Harris Associates L P acquired a new position in Icon during the second quarter worth about $238,256,000. Capital World Investors lifted its holdings in shares of Icon by 555.2% in the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock worth $272,688,000 after acquiring an additional 1,268,095 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Icon by 26.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after purchasing an additional 975,268 shares in the last quarter. Lyrical Asset Management LP acquired a new stake in shares of Icon in the 4th quarter valued at approximately $176,382,000. Finally, Norges Bank bought a new stake in shares of Icon during the 4th quarter valued at approximately $160,073,000. 95.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ICLR shares. Leerink Partners set a $145.00 price objective on shares of Icon in a research report on Thursday, May 28th. JPMorgan Chase & Co. raised their target price on shares of Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. Citigroup boosted their target price on shares of Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. Piper Sandler downgraded shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Finally, Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $168.73.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $165.76 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.14. Icon Plc has a 52 week low of $66.57 and a 52 week high of $203.91. The firm has a market cap of $12.69 billion, a PE ratio of 29.49, a price-to-earnings-growth ratio of 8.14 and a beta of 1.22. The firm’s fifty day moving average is $151.11 and its 200-day moving average is $136.43.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.